94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1543476
This article is part of the Research TopicMechanistic exploration of personalized immunotherapy for urological cancers and potential strategies for clinical translationView all 4 articles
Identification of Prognostic Hub Genes and Functional Role of BAIAP2L2 in Prostate Cancer Progression: A Transcriptomic and Experimental Study
Provisionally accepted- 1Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Beijing Municipality, China
- 2Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
- 3Xinxiang Medical University, Xinxiang, Henan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Prostate cancer (PCa) is a prevalent malignancy in men, and understanding its molecular mechanisms is crucial for identifying therapeutic targets.Methods: Transcriptomic data from prostate tumors and matched healthy tissues were obtained from The Cancer Genome Atlas (TCGA). Differential expression analysis using the DESeq2 algorithm identified differentially expressed genes (DEGs). Cox proportional hazards regression was used to evaluate prognostic significance. Clinical validation involved comparing tumor specimens with normal tissues, focusing on BAIAP2L2, which showed significant differential expression and was further examined via immunohistochemical analysis. In vitro knockdown experiments were conducted in PC3 and DU145 cell lines to assess BAIAP2L2's functional role through assays for migration, colony formation, and proliferation.Results: A total of 1,449 DEGs were identified, including 775 upregulated and 674 downregulated genes. Prognostic analysis revealed 748 genes linked to clinical outcomes, with 19 hub genes identified. QPCR confirmed significant upregulation of four candidates, including BAIAP2L2, which was also elevated in malignant tissues.BAIAP2L2 knockdown significantly impaired migration, proliferation, and viability in PCa cells.This study highlights crucial molecular mechanisms in PCa progression, particularly the significance of BAIAP2L2 as a potential therapeutic target, warranting further investigation into additional hub genes for effective targeted strategies.
Keywords: prostate cancer, BAIAP2L2, Transcriptomic Analysis, Gene Expression, biomarkers, therapeutic targets
Received: 11 Dec 2024; Accepted: 08 Apr 2025.
Copyright: © 2025 Zhan, Wang, Lian, Li, Gu, Guo, Xu and Ju. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Guanqun Ju, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, Beijing Municipality, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.